Achieve Life Sciences (ACHV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $20.00 price target.
Justin Walsh has given his Buy rating due to a combination of factors surrounding Achieve Life Sciences’ promising developments in the smoking cessation market. The company is preparing to submit a New Drug Application (NDA) for its lead product, cytisinicline, by June 2025, with a commercial launch anticipated in the third quarter of 2026. This timeline indicates a well-structured plan for bringing their product to market, which is a positive sign for potential investors.
Furthermore, cytisinicline has shown significant clinical benefits in two Phase III trials, ORCA-2 and ORCA-3, where it outperformed both placebo and existing smoking cessation therapies. The ongoing ORCA-OL study has reported no unexpected adverse events and has demonstrated excellent adherence, further supporting the drug’s potential efficacy and safety. These clinical successes, coupled with the company’s strategic planning, underpin Walsh’s optimistic outlook and Buy rating for Achieve Life Sciences.
ACHV’s price has also changed dramatically for the past six months – from $4.840 to $2.380, which is a -50.83% drop .